Last Update24 Oct 25Fair value Increased 1.29%
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.
Analyst Commentary
Following Boston Scientific's recent performance and strategic developments, analysts have issued a range of updated perspectives on the company's outlook. Their commentary reflects both confidence in the business's execution and some caution regarding future challenges.
Bullish Takeaways- Bullish analysts have continued to raise price targets, citing sustained momentum in quarterly results and upward revisions to guidance for organic growth and earnings per share.
- Strong performance in the Watchman franchise was identified as an area of acceleration. This contributes to confidence in the company’s ability to deliver upside beyond revised guidance.
- Recent acquisitions, such as the agreement to acquire Nalu Medical, are seen as strategically sound and leverage Boston Scientific’s track record in building value through early-stage investments and complementary M&A.
- The company’s three-year plan, projecting organic growth of 10%, is considered impressive and positions Boston Scientific to deliver above-average sales and EPS growth compared to large-cap MedTech peers.
- Bearish analysts caution that sales growth rates may moderate in 2026 compared to 2025. This could weigh on valuation as expectations adjust.
- There are concerns about Boston Scientific’s stock being expensive relative to sector peers, potentially limiting share price upside from current levels.
- While recent quarters have addressed some competitive fears, execution challenges in specific segments, such as electrophysiology, remain on investors’ radars.
What's in the News
- Truist raised Boston Scientific's price target to $130 from $129 after a strong Q3 earnings beat. The firm highlighted accelerated growth in the Watchman franchise and expressed confidence in further upside to updated guidance (Truist).
- Oppenheimer increased its price target for Boston Scientific to $118 from $110 following the Q2 report, maintaining a Perform rating (Oppenheimer).
- Boston Scientific announced guidance for Q4 and full year 2025, projecting net sales growth of 14.5% to 16.5% for Q4 and approximately 20% for the full year on a reported basis. GAAP EPS is expected in the range of $1.97 to $2.01 for 2025 (Company guidance).
- The company recently held an Analyst/Investor Day to review financial goals and long-term growth strategies (Company event).
Valuation Changes
- The consensus analyst price target has risen slightly to $126.14 from $124.53.
- The discount rate increased marginally, now at 7.60% compared to 7.56% previously.
- Revenue growth projections have edged lower, now estimated at 11.04%, down from 11.14%.
- The net profit margin improved, rising to 19.27% from 18.71%.
- The future P/E ratio has fallen moderately, now at 46.32x versus the previous 49.09x.
Key Takeaways
- Innovation in advanced therapies and strategic acquisitions expand market reach and support margin growth through differentiated, high-value offerings.
- Global expansion and efficiency initiatives enhance revenue diversification, improve operational margins, and drive long-term sustainable growth.
- Persistent cost pressures, competitive threats, regulatory risks, and integration challenges may limit Boston Scientific's revenue growth, pricing power, and margin resilience moving forward.
Catalysts
About Boston Scientific- Develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
- Accelerated adoption of advanced therapies like FARAPULSE (pulsed field ablation) and WATCHMAN-backed by expanded clinical indications, strong safety/efficacy data, and increased physician uptake, particularly in major global markets-positions Boston Scientific for continued above-market procedure growth, benefiting revenue and gross margins.
- Broadening global access through double-digit growth in emerging markets, especially Asia Pacific (notably in China and Japan), supports long-term international revenue diversification and offsets potential slowdowns in developed regions, driving total top-line expansion.
- Ongoing expansion into ambulatory surgery center (ASC) settings-with regulatory changes likely to facilitate increased procedure volumes-should further boost procedure capacity for minimally invasive therapies, supporting higher recurring revenue and improving capacity constraints.
- Investment in proprietary, high-margin technologies (e.g., next-gen mapping, advanced diagnostic tools, differentiated urology/neuromodulation pipelines) combined with successful integration of recent acquisitions (Axonics, SoniVie, Intera, Silk Road) expands Boston Scientific's addressable market and is likely to drive margin expansion as product mix improves.
- Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation-alongside robust cash flow-positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.
Boston Scientific Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Boston Scientific's revenue will grow by 11.1% annually over the next 3 years.
- Analysts assume that profit margins will increase from 13.5% today to 18.7% in 3 years time.
- Analysts expect earnings to reach $4.8 billion (and earnings per share of $3.17) by about September 2028, up from $2.5 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $3.6 billion.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 49.1x on those 2028 earnings, down from 63.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 29.7x.
- Analysts expect the number of shares outstanding to grow by 0.54% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.56%, as per the Simply Wall St company report.
Boston Scientific Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Risks to Boston Scientific's gross margin and net earnings persist due to ongoing cost headwinds from tariffs (with an expected $100 million impact in the second half of 2025) and the discontinuation of the ACURATE valve, which also signals vulnerability to product lifecycle challenges and regulatory pressures.
- Heightened competition from low-cost device manufacturers, especially in endoscopy and urology across Asia and Europe, as well as in MedSurg, risks eroding pricing power and market share, which could suppress future revenue expansion and margin resilience.
- Heavy reliance on continual product innovation and acquisition integration (e.g., Axonics, SoniVie, Intera Medical, Silk Road) introduces execution and integration risks; a failure to realize anticipated synergies or operational efficiencies may lead to margin compression and dilute overall earnings growth.
- Proposed and actual decreases in U.S. reimbursement rates (such as the 16% proposed cut in physician fee for LAA closure and pending evaluations on ASC code changes) introduce regulatory and payer risk, potentially impacting both volume (through slower adoption) and profit margins.
- Secular shifts such as increased adoption of procedures in ambulatory surgery centers (ASCs), price sensitivity in emerging markets, and accelerating healthcare consolidation may shift bargaining power to providers, thus restricting revenue growth opportunities and putting additional pressure on long-term margins and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $124.531 for Boston Scientific based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $140.0, and the most bearish reporting a price target of just $99.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $25.4 billion, earnings will come to $4.8 billion, and it would be trading on a PE ratio of 49.1x, assuming you use a discount rate of 7.6%.
- Given the current share price of $108.09, the analyst price target of $124.53 is 13.2% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives